FOR IMMEDIATE RELEASE
2004 Olympic Gold-Medalist Swimmer Gary Hall Jr. Joins Forces with BD to Inspire Americans to Improve Their Diabetes Care
Franklin Lakes, NJ (September 1, 2004)--2004 Olympic gold medal winner in 50-meter freestyle swimming, Gary Hall Jr., partners with BD (Becton, Dickinson and Company) (NYSE:BDX), one of the world's largest makers of diabetes care products, to help educate Americans about good diabetes care.
"Diabetes management is like swimming; it's up to the individual. People with diabetes can easily access the tools and information they need to ensure a healthy life," says nine-time Olympic medalist Gary Hall Jr., who has Type I diabetes. "I won the Olympic gold medal because I am healthy and in top competitive shape thanks to help from BD. BD insulin syringes, pen needles and lancets help me manage my diabetes easily and comfortably so that I can focus on my swimming."
Diabetes affects more than 18 million Americans today and more than 5 million of them go undiagnosed according to the American Diabetes Association. Diabetes is the sixth largest cause of death in the U.S. and the leading cause of blindness in Americans ages 20-74. Type I diabetes, like Hall's, accounts for between five and ten percent of the total people with diabetes; Type II diabetes accounts for the remainder.
"BD is proud to join forces with Gary Hall. We see him as an inspiration to all people with diabetes because every day he proves that diabetes is not a limitation to a dream," says Bill Marshall, President, Diabetes Care, BD Medical. "We hope to help people with diabetes understand that, like Gary, they can take control of their disease—they just need the right tools, information and support."
Hall will be the national spokesperson for BD's insulin delivery products and will be partnering with the company on a nationwide education initiative immediately following the 2004 Games.
"Injecting insulin can be intimidating for someone who has never done it before," says Hall, who has used BD products since he was first diagnosed with diabetes in 1999. "With BD insulin syringes and pen needles, my injections are virtually pain free. That's important to me since I inject insulin six to eight times a day on a regular day and as many as 10 to 12 times a day before a competition." The long-term health of a person with diabetes comes down to how closely that person controls their blood sugar. Insulin therapy is part of an overall diabetes management approach that includes appropriate nutrition, frequent blood glucose monitoring and exercise.
As part of his partnership with BD, Hall also will be the national spokesperson for BD's sports medicine brand, ACE®, which offers a full line of braces, bandages, sports tape and hot & cold therapy products to help treat and support weak muscles, tendons and ligaments and to help reduce the chance of injury recurrence.
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of $4.528 billion.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; changes in BD's sales volume and product mix; B''s ability to achieve its cost savings objectives; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statement.
200 East Randolph Dr.
Chicago, IL 60601
|Return to the Top of This Page|
Last Updated: Wednesday November 05, 2014 21:27:24
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2018. Comments and Feedback.